UPDATE: Raymond James Upgrades Amsurg Following Sheridan Health Acquisition
In a report issued Friday, Raymond James upgraded its rating of Amsurg (NASDAQ: AMSG) from Market Perform to Strong Buy with a target price of $60.
Analyst John W. Ransom has raised his estimates for Amsurg with its acquisition of Sheridan Health on Thursday. This merger should help boost organic and EPS growth, as well.
Ransom also raised his EPS estimate from $2.77 to $3.15 for 2015.
Amsurg will open Friday at $45.74.
Latest Ratings for AMSG
|Sep 2016||Citigroup||Initiates Coverage on||Buy|
|Jun 2016||Wells Fargo||Initiates Coverage on||Market Perform|
|Apr 2016||Mizuho||Initiates Coverage on||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.